Dr. Michael Har-Noy’s Compassionate Use-Phase I/II Trial of CRCL-AlloVaxTM in Thailand

21 Jan

Dr. Michael Har-Noy has announced that his experimental individualized cancer vaccine, known as CRCL-AlloVaxTM, is now available under a combined “Compassionate Use” /Phase I/II study protocol in Bangkok, Thailand.  Dr. Michael Har-Noy says this experimental vaccine is produced from a sample of the patient’s own tumor. The vaccine can be produced from viurtually any type of solid tumor, including those arising from the breast, prostate, pancreas, lung,  kidney, gastrointestinal tract, bladder, and thyroid gland.  Dr. Michael Har-Noy indicates that the vaccine can also be produced from gynecologic tumors (those arising from the vagina, uterus, cervix, and ovary), melanomas, sarcomas (including Kaposi’s), and lymphomas.

Dr. Michael Har-Noy has created a new website, www.immunocare.net, where patients may register for the upcoming Phase I/II trial.

Dr. Michael Har-Noy indicates that in order to qualify for the study protocol, patients should meet the following criteria:  1) have a tumor that is not responding to chemotherapy, or are seeking an alternative to chemotherapy, 2) be generally healthy, 3) agree to try an experimental protocol to train his/her immune system to potentially kill the tumor and prevent further spread, 4) be willing to travel to Bangkok for a month, 5) be willing to cooperate with study doctors and study protocol after their return from Bangkok, and 6) be able to pay the cost of participation.

Dr. Michael Har-Noy says that patients wanting more information should visit www.immunocare.net On the website they can: 1) view a slide presentation describing the technology, 2) read detailed information about the trial, 3) chat with a specialist live in their native language, 4) submit questions by email to study specialists, and 5) register for the trial.

This clinical trial, indicates Dr. Michael Har-Noy, will be conducted in compliance with all international standards for Good Clinical Practices (GCP/ICH).  All patients will be provided with an informed consent document and a contract.  Dr. Michael Har-Noy adds that all trial protocols are approved and monitored by an Institutional Review Board (Ethics Committee).  Also, an independent Data Safety Monitoring Board will oversee the study. The study’s principle investigator is a physician who was trained in the United States and who is board certified in hematology and oncology.

Source: www.michaelhar-noy.com


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: